Why Is Cellebrite (CLBT) Stock Down? A 2.6% Guide Cut and a New CEO

TL;DR

• Cellebrite (Nasdaq: CLBT) traded at $10.50 pre-market on August 13, down 31.2% from Wednesday's $15.25 close. That is a pre-market quote taken at 7:49am ET, not a close, so the regular session is the number that will settle it.
• The company cut its full-year 2026 ARR guide to $550-560 million from $567-573 million and its revenue guide to $555-561 million from $565-571 million. At the midpoints that is $15 million off ARR, or 2.6%.
• It raised the adjusted EBITDA target in the same release, to $153-159 million from $149-155 million.
• Q2 ARR of $507.8 million came in below management's own guide of $510-513 million, given three months earlier. Revenue of $131.1 million landed inside the $130-133 million range.
• Thomas E. Hogan is out as CEO, effective immediately, replaced by Shiven Ramji, who joined the company as President of Products and Technology in May 2026.

Why Is Cellebrite (CLBT) Stock Down?

Cellebrite lowered its full-year ARR and revenue targets and announced an immediate change of chief executive in the same pre-market release. Incoming CEO Shiven Ramji attributed the shortfall to "longer sales cycles and less expansion from Inseyets conversions than anticipated." The stock fell 31.2% pre-market, taking roughly $1.2 billion off a $3.8 billion market capitalisation.

The Board

The revenue line did its job. The recurring line did not, and the guide followed it down.

Two and a Half Percent

That is the size of the cut. Cellebrite told investors in May to expect $567-573 million of ARR by the end of 2026. This morning it said $550-560 million. Midpoint to midpoint, $570 million became $555 million.

Against that, the market took about $1.18 billion off the equity in pre-market trade, from $3.80 billion at Wednesday's close to roughly $2.62 billion on 249.4 million shares. That is around 79 times the dollar value of the guidance reduction.

Numbers that far apart usually mean the market is repricing something other than 2026. My read is that it is repricing the growth rate itself. A software business trading on recurring revenue is valued off the slope, and the slope is what moved.

Management Missed Its Own ARR Guide

$507.8 million against a $510-513 million range. It is a small miss in absolute terms, two to five million dollars, and it is the one figure in the release that management had personally underwritten twelve weeks earlier. Revenue at $131.1 million sat comfortably inside its own $130-133 million guide, and adjusted EBITDA of $31.8 million produced a 24.2% margin.

So the profit side of this quarter is fine. Subscription revenue rose 16% to $119.5 million, trailing twelve-month free cash flow reached $144.2 million at a 28.0% margin, and the raised EBITDA target says management expects to keep converting. Growth is the line that broke.

What the Second Half Has to Deliver

Run the ARR ramp forward and the guide starts to look demanding. Cellebrite closed Q1 at $493.0 million and Q2 at $507.8 million, an add of $14.8 million in the quarter. Getting to the $555 million midpoint by December needs $47.2 million more across two quarters, roughly $23.6 million each.

That is about 1.6 times the pace the company just posted, in a period management has described as having longer sales cycles. Cellebrite's business does skew toward the back half of the year, government procurement being what it is, so some acceleration is normal rather than heroic. I still think the reduced guide has less cushion in it than a 2.6% trim implies, and that is a fair part of why the shares are where they are.

Hogan Out, Ramji In

Thomas E. Hogan arrived as Executive Chairman in August 2023, took the interim CEO job in January 2025 and the permanent one in August 2025. He leaves the role today. Shiven Ramji, who joined in May 2026 to run products and technology, takes it and a board seat with immediate effect.

Three months in the building is not much of a runway before owning a guidance reset in public. It can be read two ways. A board that moves this fast has usually concluded the problem is execution rather than the end market, which is the more fixable diagnosis. It also means the person now defending the $555 million midpoint had no hand in setting the $570 million one.

Ramji said growth held up in Asia-Pacific, EMEA and US Federal, and that the company is "taking a more measured view" of what newer products contribute near term. I would treat that last phrase as the durable one. It is a signal about how the next few guides get set, and it is the sentence I will check the Q3 release against.

What Would Change My Mind

A 31% drawdown on a 2.6% guide cut is the kind of gap that either corrects or turns out to have been early. Three things decide it, and none of them arrives before the Q3 print:

• Net new ARR above roughly $20 million in Q3. Below that the full-year midpoint stops being reachable and the guide gets cut a second time.
• Inseyets conversion economics. Management named expansion on conversions as the shortfall. Either the attach rates recover or the platform migration stops being a growth story and becomes a maintenance one.
• Whether the EBITDA raise survives. Holding a 28% margin while ARR decelerates is a good outcome. Holding it by spending less on sales while sales cycles lengthen is the version that costs 2027.

I am not putting a price target on this. The valuation case depends entirely on which ARR trajectory is real, and one quarter does not tell me. What I will say plainly is that the raised EBITDA target is doing more work in this release than most of the coverage will give it credit for, and a business generating $144 million of trailing free cash flow does not become uninvestable because a subscription line missed by four million dollars.

No options play is logged here. I could not source a live chain before the open, and a structure without a price is not a call anyone can score later.

The One-Line Read

A $15 million guide cut cost $1.2 billion because the market repriced the slope rather than the year. The CEO change on the same morning makes that slope hard to argue with.

Other movers and data this morning: the day's hour-by-hour timetable has July PPI at 8:30am and Applied Materials after the close, the PPI setup is here, and Leslie's fell around 44% overnight on a going-concern warning. The rest of the week's reporters are in the earnings calendar.